Hospice & Home Health News 2026 October23
LeadingAge Advocacy Delivers: CMS Adopts All HOPE Guidance Recommendations.
In a clear demonstration of effective advocacy, the Centers for Medicare and Medicaid Advocacy (CMS) has incorporated all recommendations for Hospice Outcomes and Patient Evaluation (HOPE) updates recommended by LeadingAge to the agency. First, the new HOPE guidance manual and accompanying tools released recently by CMS reflect changes requested by LeadingAge, in collaboration with the National Alliance for Care at Home and the National Partnership for Healthcare and Hospice Innovation, in a March 30, 2026 letter regarding updates to the tool itself and to the guidance manual (all updates are available on the download section of this page). Specifically, CMS has taken the pen to the manual to update language to clearly “to include all assessment activities to include observation and/or focused clinical assessments which could be conducted by an LPN/LVN to complete the [Symptom Follow Up Visit] SFV.” This was a significant concern as in many states, licensed nurses have stricter scope of practices which prevented them from completing the HOPE when it was considered an “assessment.” CMS also clarified that hospices can still conduct the Hospice Update Visit even if they are outside the timeframe. CMS has also made specific updates to coding direction for A1905 Living Arrangements and N0500 Scheduled Opioids to provide clarity to questions many providers had. Members can review the full change document here. CMS took action on another request, also made in the March 30 letter, to waive the compliance threshold for the first quarter of HOPE implementation. This is reflected in the CY2027 Hospice Final Rule, which waives HOPE reporting from October 1 to December 31, 2025 from impacting compliance thresholds for hospices. LeadingAge will have a longer article later this week discussing the changes, and we will subsequently update the HOPE Implementation Guide on the LeadingAge Learning HUB.
Medline Recalls All Beds and Associated Parts.
On October 14, 2026, Medline released field notification letter R-25-242-X9 recalling all Medline brand beds and associated parts and accessories. The notice of voluntary field action to initiate product removal, discontinuation, and market exit issued on October 14 is an update to previous notifications that only affected certain product lines. According to the notice, the reason for recall is related to “electrical system safety risks that may result in fire and entrapment risk from the use of any bed accessories.” Medline advises: “Immediately unplug the bed and any associated battery packs or batteries from the bed or accessories,” and “Do not use the electrical functionality of the bed.” Medline states that the bed and mattress can continue to be used in manual mode until the bed can be replaced. Electrical adjustments should be made in emergency situations only. Should the bed be plugged back in for emergency use, extensions cords cannot be used. Bed accessories, including side rails, should also not be used. Adverse events should be reported to Medline QualityAssurance@medline.com. Medline will provide customers with a safety label to be placed on beds. Customers should contact the provider or distributor of the bed for information on removal and replacement of the bed. Find the field notification letter and Medline item list here.
Here is your weekly Home Health Weekly Recap from National.
Here is your weekly
Hospice Weekly Recap
from National.










